Stem definition | Drug id | CAS RN |
---|---|---|
proteasome inhibitors | 5067 | 1072833-77-2 |
None
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 3.61 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.50 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 97 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 30, 2017 | PMDA | Takeda Pharmaceutical Company Limited | |
Nov. 21, 2016 | EMA | Takeda Pharma A/S | |
Nov. 20, 2015 | FDA | MILLENNIUM PHARMS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Diarrhoea | 798.24 | 20.83 | 1051 | 18615 | 587425 | 49998033 |
Neuropathy peripheral | 521.04 | 20.83 | 372 | 19294 | 96385 | 50489073 |
Death | 488.80 | 20.83 | 614 | 19052 | 324765 | 50260693 |
Adverse event | 267.11 | 20.83 | 182 | 19484 | 43581 | 50541877 |
Thrombocytopenia | 264.27 | 20.83 | 285 | 19381 | 127388 | 50458070 |
Platelet count decreased | 248.26 | 20.83 | 247 | 19419 | 100479 | 50484979 |
Pneumonia | 216.49 | 20.83 | 462 | 19204 | 377939 | 50207519 |
Plasma cell myeloma recurrent | 176.74 | 20.83 | 58 | 19608 | 2600 | 50582858 |
Plasma cell myeloma | 167.07 | 20.83 | 120 | 19546 | 31202 | 50554256 |
Off label use | 160.11 | 20.83 | 474 | 19192 | 473952 | 50111506 |
Product physical issue | 138.51 | 20.83 | 55 | 19611 | 4277 | 50581181 |
Nausea | 134.30 | 20.83 | 584 | 19082 | 704814 | 49880644 |
Constipation | 129.85 | 20.83 | 247 | 19419 | 185461 | 50399997 |
White blood cell count decreased | 123.75 | 20.83 | 187 | 19479 | 116535 | 50468923 |
No adverse event | 120.99 | 20.83 | 102 | 19564 | 33476 | 50551982 |
Full blood count decreased | 106.46 | 20.83 | 80 | 19586 | 22266 | 50563192 |
Cytopenia | 101.41 | 20.83 | 55 | 19611 | 8720 | 50576738 |
Product dose omission issue | 91.64 | 20.83 | 213 | 19453 | 183625 | 50401833 |
Laboratory test abnormal | 90.88 | 20.83 | 74 | 19592 | 23134 | 50562324 |
Neutrophil count decreased | 86.74 | 20.83 | 98 | 19568 | 45928 | 50539530 |
Vomiting | 83.00 | 20.83 | 376 | 19290 | 460382 | 50125076 |
Adverse drug reaction | 70.93 | 20.83 | 97 | 19569 | 55125 | 50530333 |
Fatigue | 68.66 | 20.83 | 489 | 19177 | 707112 | 49878346 |
Influenza | 58.64 | 20.83 | 116 | 19550 | 89422 | 50496036 |
Drug ineffective | 57.00 | 20.83 | 149 | 19517 | 819184 | 49766274 |
Dehydration | 48.80 | 20.83 | 150 | 19516 | 152299 | 50433159 |
Neutropenia | 45.89 | 20.83 | 144 | 19522 | 147821 | 50437637 |
Plasmacytoma | 45.47 | 20.83 | 21 | 19645 | 2364 | 50583094 |
Muscle spasms | 44.40 | 20.83 | 128 | 19538 | 125425 | 50460033 |
Paraesthesia | 43.90 | 20.83 | 124 | 19542 | 120119 | 50465339 |
Drug interaction | 43.29 | 20.83 | 12 | 19654 | 199609 | 50385849 |
Rash | 42.56 | 20.83 | 303 | 19363 | 437168 | 50148290 |
Asthenia | 40.87 | 20.83 | 237 | 19429 | 318805 | 50266653 |
Monoclonal immunoglobulin present | 40.69 | 20.83 | 14 | 19652 | 726 | 50584732 |
Body dysmorphic disorder | 40.49 | 20.83 | 11 | 19655 | 254 | 50585204 |
Toxicity to various agents | 40.44 | 20.83 | 16 | 19650 | 212483 | 50372975 |
Product packaging quantity issue | 39.07 | 20.83 | 15 | 19651 | 1065 | 50584393 |
Accidental exposure to product | 38.24 | 20.83 | 46 | 19620 | 23011 | 50562447 |
Condition aggravated | 37.65 | 20.83 | 36 | 19630 | 297022 | 50288436 |
COVID-19 | 37.46 | 20.83 | 66 | 19600 | 46596 | 50538862 |
Illness | 35.95 | 20.83 | 46 | 19620 | 24494 | 50560964 |
Product blister packaging issue | 35.90 | 20.83 | 9 | 19657 | 150 | 50585308 |
Light chain analysis increased | 35.30 | 20.83 | 14 | 19652 | 1084 | 50584374 |
Treatment failure | 34.42 | 20.83 | 6 | 19660 | 137631 | 50447827 |
Arthralgia | 34.13 | 20.83 | 75 | 19591 | 438627 | 50146831 |
Glossodynia | 33.84 | 20.83 | 3 | 19663 | 115566 | 50469892 |
Infusion related reaction | 33.53 | 20.83 | 12 | 19654 | 169545 | 50415913 |
Cardiac amyloidosis | 33.21 | 20.83 | 12 | 19654 | 719 | 50584739 |
Peripheral swelling | 33.16 | 20.83 | 163 | 19503 | 205773 | 50379685 |
Cataract | 33.04 | 20.83 | 63 | 19603 | 47237 | 50538221 |
Pain | 32.44 | 20.83 | 116 | 19550 | 578787 | 50006671 |
Injection site pain | 32.19 | 20.83 | 3 | 19663 | 111021 | 50474437 |
Therapeutic product effect decreased | 31.77 | 20.83 | 7 | 19659 | 136043 | 50449415 |
COVID-19 pneumonia | 31.24 | 20.83 | 26 | 19640 | 8369 | 50577089 |
Vitiligo | 31.22 | 20.83 | 13 | 19653 | 1141 | 50584317 |
Drug hypersensitivity | 31.12 | 20.83 | 31 | 19635 | 250979 | 50334479 |
Hepatic enzyme increased | 30.26 | 20.83 | 8 | 19658 | 137372 | 50448086 |
Product packaging issue | 29.94 | 20.83 | 12 | 19654 | 955 | 50584503 |
Joint ankylosis | 29.04 | 20.83 | 11 | 19655 | 753 | 50584705 |
Monoclonal immunoglobulin increased | 28.93 | 20.83 | 7 | 19659 | 100 | 50585358 |
Discomfort | 28.74 | 20.83 | 4 | 19662 | 108376 | 50477082 |
Wound | 27.83 | 20.83 | 4 | 19662 | 105790 | 50479668 |
Decreased appetite | 27.47 | 20.83 | 152 | 19514 | 200771 | 50384687 |
Back pain | 27.17 | 20.83 | 162 | 19504 | 219868 | 50365590 |
VIth nerve paresis | 25.25 | 20.83 | 6 | 19660 | 79 | 50585379 |
Blood potassium decreased | 24.32 | 20.83 | 48 | 19618 | 36897 | 50548561 |
Product use issue | 24.22 | 20.83 | 14 | 19652 | 149461 | 50435997 |
Ageusia | 24.11 | 20.83 | 26 | 19640 | 11557 | 50573901 |
Musculoskeletal stiffness | 23.89 | 20.83 | 10 | 19656 | 128471 | 50456987 |
Hypoglossal nerve paresis | 23.60 | 20.83 | 6 | 19660 | 106 | 50585352 |
Blood immunoglobulin G increased | 23.12 | 20.83 | 11 | 19655 | 1324 | 50584134 |
Headache | 23.03 | 20.83 | 110 | 19556 | 506425 | 50079033 |
Eye swelling | 22.32 | 20.83 | 33 | 19633 | 20111 | 50565347 |
Product packaging difficult to open | 22.03 | 20.83 | 5 | 19661 | 53 | 50585405 |
Haemorrhoidal haemorrhage | 21.74 | 20.83 | 15 | 19651 | 3652 | 50581806 |
Tumour lysis syndrome | 21.62 | 20.83 | 20 | 19646 | 7401 | 50578057 |
Tachycardia | 21.60 | 20.83 | 6 | 19660 | 99757 | 50485701 |
Product use in unapproved indication | 21.56 | 20.83 | 9 | 19657 | 115810 | 50469648 |
Hypertension | 20.96 | 20.83 | 31 | 19635 | 211172 | 50374286 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Death | 491.83 | 20.83 | 802 | 17375 | 341282 | 29215068 |
Neuropathy peripheral | 443.83 | 20.83 | 359 | 17818 | 70668 | 29485682 |
Pneumonia | 299.20 | 20.83 | 625 | 17552 | 319547 | 29236803 |
Adverse event | 283.83 | 20.83 | 153 | 18024 | 15138 | 29541212 |
Diarrhoea | 271.41 | 20.83 | 615 | 17562 | 332083 | 29224267 |
Off label use | 234.91 | 20.83 | 547 | 17630 | 300253 | 29256097 |
Platelet count decreased | 184.23 | 20.83 | 271 | 17906 | 104401 | 29451949 |
No adverse event | 183.09 | 20.83 | 121 | 18056 | 17357 | 29538993 |
Thrombocytopenia | 175.37 | 20.83 | 304 | 17873 | 134519 | 29421831 |
Plasma cell myeloma recurrent | 162.36 | 20.83 | 67 | 18110 | 3616 | 29552734 |
Plasma cell myeloma | 161.47 | 20.83 | 153 | 18024 | 36962 | 29519388 |
Product physical issue | 156.82 | 20.83 | 56 | 18121 | 2032 | 29554318 |
Full blood count decreased | 153.79 | 20.83 | 105 | 18072 | 15887 | 29540463 |
Laboratory test abnormal | 119.67 | 20.83 | 95 | 18082 | 18090 | 29538260 |
Fatigue | 109.34 | 20.83 | 433 | 17744 | 316388 | 29239962 |
Constipation | 108.01 | 20.83 | 225 | 17952 | 113935 | 29442415 |
Rash | 106.73 | 20.83 | 306 | 17871 | 189513 | 29366837 |
Drug interaction | 104.05 | 20.83 | 4 | 18173 | 197381 | 29358969 |
Adverse drug reaction | 94.95 | 20.83 | 94 | 18083 | 23926 | 29532424 |
White blood cell count decreased | 91.62 | 20.83 | 175 | 18002 | 83187 | 29473163 |
Influenza | 83.10 | 20.83 | 115 | 18062 | 41766 | 29514584 |
Peripheral swelling | 81.63 | 20.83 | 143 | 18034 | 63596 | 29492754 |
Product dose omission issue | 80.81 | 20.83 | 181 | 17996 | 96202 | 29460148 |
Light chain analysis increased | 80.68 | 20.83 | 29 | 18148 | 1072 | 29555278 |
Toxicity to various agents | 66.61 | 20.83 | 13 | 18164 | 173648 | 29382702 |
COVID-19 | 61.34 | 20.83 | 92 | 18085 | 35922 | 29520428 |
Cytopenia | 53.35 | 20.83 | 46 | 18131 | 9813 | 29546537 |
Accidental exposure to product | 51.86 | 20.83 | 47 | 18130 | 10706 | 29545644 |
Back pain | 50.73 | 20.83 | 158 | 18019 | 102126 | 29454224 |
Thrombosis | 41.94 | 20.83 | 86 | 18091 | 42959 | 29513391 |
Monoclonal immunoglobulin present | 41.85 | 20.83 | 17 | 18160 | 880 | 29555470 |
Product packaging issue | 38.55 | 20.83 | 14 | 18163 | 533 | 29555817 |
Muscle spasms | 38.41 | 20.83 | 107 | 18070 | 64975 | 29491375 |
Product blister packaging issue | 37.72 | 20.83 | 9 | 18168 | 73 | 29556277 |
Product use in unapproved indication | 36.62 | 20.83 | 5 | 18172 | 86870 | 29469480 |
Lower respiratory tract infection | 35.89 | 20.83 | 61 | 18116 | 26441 | 29529909 |
Product packaging quantity issue | 33.99 | 20.83 | 14 | 18163 | 751 | 29555599 |
Full blood count increased | 33.48 | 20.83 | 14 | 18163 | 780 | 29555570 |
Tachycardia | 30.91 | 20.83 | 4 | 18173 | 72406 | 29483944 |
Nausea | 30.53 | 20.83 | 291 | 17886 | 288964 | 29267386 |
Neutropenia | 29.45 | 20.83 | 159 | 18018 | 131552 | 29424798 |
Nasopharyngitis | 29.38 | 20.83 | 92 | 18085 | 59573 | 29496777 |
Morganella infection | 29.31 | 20.83 | 11 | 18166 | 460 | 29555890 |
Hypertension | 27.52 | 20.83 | 19 | 18158 | 116595 | 29439755 |
Cryptosporidiosis infection | 26.90 | 20.83 | 10 | 18167 | 407 | 29555943 |
Rhabdomyolysis | 26.84 | 20.83 | 3 | 18174 | 60805 | 29495545 |
Asthenia | 26.49 | 20.83 | 224 | 17953 | 215026 | 29341324 |
Illness | 26.13 | 20.83 | 26 | 18151 | 6648 | 29549702 |
Condition aggravated | 26 | 20.83 | 31 | 18146 | 146264 | 29410086 |
Bronchial haemorrhage | 25.35 | 20.83 | 11 | 18166 | 672 | 29555678 |
Unevaluable event | 24.88 | 20.83 | 56 | 18121 | 29795 | 29526555 |
JC virus CSF test positive | 24.66 | 20.83 | 7 | 18170 | 118 | 29556232 |
Light chain disease | 24.45 | 20.83 | 7 | 18170 | 122 | 29556228 |
Chillblains | 24.36 | 20.83 | 5 | 18172 | 18 | 29556332 |
Laryngeal cancer metastatic | 24.11 | 20.83 | 6 | 18171 | 59 | 29556291 |
Insomnia | 23.94 | 20.83 | 113 | 18064 | 88648 | 29467702 |
Hypotension | 23.51 | 20.83 | 53 | 18124 | 194301 | 29362049 |
Cataract | 23.32 | 20.83 | 46 | 18131 | 22332 | 29534018 |
Spinal pain | 22.94 | 20.83 | 21 | 18156 | 4843 | 29551507 |
Immunoglobulins decreased | 21.84 | 20.83 | 10 | 18167 | 694 | 29555656 |
Plasmacytoma | 21.57 | 20.83 | 17 | 18160 | 3198 | 29553152 |
Otitis externa bacterial | 21.19 | 20.83 | 4 | 18173 | 8 | 29556342 |
Pneumonia influenzal | 21.06 | 20.83 | 12 | 18165 | 1318 | 29555032 |
Seizure | 20.89 | 20.83 | 16 | 18161 | 93107 | 29463243 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Diarrhoea | 600.76 | 19.91 | 971 | 21573 | 721733 | 63754455 |
Neuropathy peripheral | 565.84 | 19.91 | 405 | 22139 | 117120 | 64359068 |
Pneumonia | 517.85 | 19.91 | 791 | 21753 | 558785 | 63917403 |
Platelet count decreased | 376.21 | 19.91 | 372 | 22172 | 167339 | 64308849 |
Off label use | 359.00 | 19.91 | 722 | 21822 | 632084 | 63844104 |
Thrombocytopenia | 330.01 | 19.91 | 398 | 22146 | 223403 | 64252785 |
Death | 284.00 | 19.91 | 560 | 21984 | 482145 | 63994043 |
Plasma cell myeloma recurrent | 220.05 | 19.91 | 74 | 22470 | 3991 | 64472197 |
Plasma cell myeloma | 219.35 | 19.91 | 158 | 22386 | 45917 | 64430271 |
Product physical issue | 160.23 | 19.91 | 56 | 22488 | 3393 | 64472795 |
No adverse event | 152.26 | 19.91 | 105 | 22439 | 28456 | 64447732 |
White blood cell count decreased | 145.69 | 19.91 | 224 | 22320 | 157613 | 64318575 |
Neutrophil count decreased | 122.76 | 19.91 | 143 | 22401 | 77053 | 64399135 |
Product dose omission issue | 121.15 | 19.91 | 232 | 22312 | 194515 | 64281673 |
Full blood count decreased | 117.96 | 19.91 | 82 | 22462 | 22500 | 64453688 |
Rash | 112.92 | 19.91 | 384 | 22160 | 458165 | 64018023 |
Constipation | 98.45 | 19.91 | 235 | 22309 | 229102 | 64247086 |
Influenza | 95.13 | 19.91 | 149 | 22395 | 106382 | 64369806 |
Drug interaction | 84.26 | 19.91 | 13 | 22531 | 362070 | 64114118 |
Toxicity to various agents | 74.15 | 19.91 | 18 | 22526 | 363495 | 64112693 |
Fatigue | 72.71 | 19.91 | 478 | 22066 | 748252 | 63727936 |
Cytopenia | 71.16 | 19.91 | 52 | 22492 | 15419 | 64460769 |
Nausea | 71.13 | 19.91 | 493 | 22051 | 785307 | 63690881 |
Laboratory test abnormal | 60.54 | 19.91 | 57 | 22487 | 24006 | 64452182 |
COVID-19 | 59.35 | 19.91 | 92 | 22452 | 65048 | 64411140 |
Product blister packaging issue | 52.79 | 19.91 | 12 | 22532 | 144 | 64476044 |
Light chain analysis increased | 52.28 | 19.91 | 19 | 22525 | 1289 | 64474899 |
Plasmacytoma | 52.22 | 19.91 | 26 | 22518 | 3844 | 64472344 |
Dehydration | 51.77 | 19.91 | 180 | 22364 | 216583 | 64259605 |
Product packaging quantity issue | 46.08 | 19.91 | 16 | 22528 | 950 | 64475238 |
Drug ineffective | 41.36 | 19.91 | 153 | 22391 | 840094 | 63636094 |
Pain | 41.36 | 19.91 | 82 | 22462 | 553429 | 63922759 |
Neutropenia | 39.39 | 19.91 | 177 | 22367 | 239447 | 64236741 |
Product packaging issue | 38.29 | 19.91 | 14 | 22530 | 966 | 64475222 |
Body dysmorphic disorder | 37.14 | 19.91 | 10 | 22534 | 249 | 64475939 |
Cardiac amyloidosis | 36.68 | 19.91 | 15 | 22529 | 1400 | 64474788 |
Peripheral swelling | 36.27 | 19.91 | 157 | 22387 | 208996 | 64267192 |
Accidental exposure to product | 35.61 | 19.91 | 45 | 22499 | 26319 | 64449869 |
Vomiting | 34.90 | 19.91 | 319 | 22225 | 550798 | 63925390 |
Hypertension | 34.83 | 19.91 | 24 | 22520 | 259237 | 64216951 |
Anaemia | 33.08 | 19.91 | 236 | 22308 | 378444 | 64097744 |
Adverse drug reaction | 33.02 | 19.91 | 58 | 22486 | 45406 | 64430782 |
Drug hypersensitivity | 31.96 | 19.91 | 22 | 22522 | 237793 | 64238395 |
Product use in unapproved indication | 31.82 | 19.91 | 11 | 22533 | 176607 | 64299581 |
Muscle spasms | 31.81 | 19.91 | 115 | 22429 | 140908 | 64335280 |
Headache | 31.12 | 19.91 | 89 | 22455 | 529378 | 63946810 |
COVID-19 pneumonia | 30.34 | 19.91 | 33 | 22511 | 16471 | 64459717 |
Hypotension | 29.66 | 19.91 | 55 | 22489 | 380919 | 64095269 |
Tachycardia | 29.31 | 19.91 | 8 | 22536 | 149571 | 64326617 |
Sepsis | 29.17 | 19.91 | 158 | 22386 | 230183 | 64246005 |
Monoclonal immunoglobulin present | 29.09 | 19.91 | 11 | 22533 | 834 | 64475354 |
Arthralgia | 28.50 | 19.91 | 71 | 22473 | 442189 | 64033999 |
Pneumonia influenzal | 28.40 | 19.91 | 15 | 22529 | 2507 | 64473681 |
Injection site pain | 28.28 | 19.91 | 3 | 22541 | 111405 | 64364783 |
Cryptosporidiosis infection | 28.12 | 19.91 | 10 | 22534 | 637 | 64475551 |
Asthenia | 27.68 | 19.91 | 249 | 22295 | 427795 | 64048393 |
Musculoskeletal stiffness | 27.33 | 19.91 | 5 | 22539 | 123201 | 64352987 |
Full blood count increased | 27.31 | 19.91 | 9 | 22535 | 455 | 64475733 |
Vitiligo | 27.22 | 19.91 | 13 | 22531 | 1755 | 64474433 |
Condition aggravated | 27.06 | 19.91 | 56 | 22488 | 372370 | 64103818 |
Taste disorder | 26.95 | 19.91 | 24 | 22520 | 9409 | 64466779 |
Cataract | 26.92 | 19.91 | 57 | 22487 | 51205 | 64424983 |
JC virus CSF test positive | 26.87 | 19.91 | 7 | 22537 | 153 | 64476035 |
Joint ankylosis | 26.44 | 19.91 | 10 | 22534 | 759 | 64475429 |
Back pain | 26.08 | 19.91 | 163 | 22381 | 250008 | 64226180 |
Hypercalcaemia | 25.35 | 19.91 | 42 | 22502 | 31374 | 64444814 |
Upper respiratory tract inflammation | 25.22 | 19.91 | 16 | 22528 | 3766 | 64472422 |
Light chain disease | 24.82 | 19.91 | 7 | 22537 | 208 | 64475980 |
Herpes zoster | 24.56 | 19.91 | 72 | 22472 | 79115 | 64397073 |
Immunoglobulins decreased | 24.37 | 19.91 | 11 | 22533 | 1307 | 64474881 |
Cardiac failure | 24.18 | 19.91 | 101 | 22443 | 132272 | 64343916 |
Hypoglossal nerve paresis | 24.08 | 19.91 | 6 | 22538 | 109 | 64476079 |
Squamous cell carcinoma of skin | 24.05 | 19.91 | 25 | 22519 | 11851 | 64464337 |
Morganella infection | 23.83 | 19.91 | 10 | 22534 | 996 | 64475192 |
Nasopharyngitis | 23.81 | 19.91 | 133 | 22411 | 195940 | 64280248 |
Treatment failure | 23.35 | 19.91 | 6 | 22538 | 116810 | 64359378 |
Therapeutic product effect decreased | 22.91 | 19.91 | 6 | 22538 | 115345 | 64360843 |
Laryngeal cancer metastatic | 22.83 | 19.91 | 5 | 22539 | 50 | 64476138 |
VIth nerve paresis | 22.82 | 19.91 | 6 | 22538 | 136 | 64476052 |
Infusion related reaction | 22.37 | 19.91 | 15 | 22529 | 164452 | 64311736 |
Bronchial haemorrhage | 21.96 | 19.91 | 10 | 22534 | 1212 | 64474976 |
Blood calcium abnormal | 21.72 | 19.91 | 10 | 22534 | 1244 | 64474944 |
Blood immunoglobulin G increased | 20.87 | 19.91 | 11 | 22533 | 1830 | 64474358 |
Polyneuropathy | 20.82 | 19.91 | 30 | 22514 | 19864 | 64456324 |
Blood pressure increased | 20.59 | 19.91 | 18 | 22526 | 172534 | 64303654 |
Hepatic enzyme increased | 20.31 | 19.91 | 10 | 22534 | 129933 | 64346255 |
None
Source | Code | Description |
---|---|---|
ATC | L01XG03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Proteasome inhibitors |
FDA MoA | N0000175075 | Proteasome Inhibitors |
FDA EPC | N0000175604 | Proteasome Inhibitor |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D011480 | Protease Inhibitors |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:50266 | Prodrugs |
CHEBI has role | CHEBI:52726 | proteasome inhibitors |
CHEBI has role | CHEBI:68495 | Type I cell-death inducers |
CHEBI has role | CHEBI:71031 | orphan drugs |
CHEBI has role | CHEBI:49103 | drug metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Multiple myeloma | indication | 109989006 | DOID:9538 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.27 | acidic |
pKa2 | 12.17 | acidic |
pKa3 | 13.45 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 2.3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 9233115 | Aug. 12, 2024 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 9233115 | Aug. 12, 2024 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 4MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 9233115 | Aug. 12, 2024 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 2.3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 8003819 | Aug. 6, 2027 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 2.3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 8530694 | Aug. 6, 2027 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 2.3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 8871745 | Aug. 6, 2027 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 8003819 | Aug. 6, 2027 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 8530694 | Aug. 6, 2027 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 8871745 | Aug. 6, 2027 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 4MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 8003819 | Aug. 6, 2027 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 4MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 8530694 | Aug. 6, 2027 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 4MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 8871745 | Aug. 6, 2027 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 2.3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 9175017 | June 16, 2029 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 9175017 | June 16, 2029 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 4MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 9175017 | June 16, 2029 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 2.3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 7442830 | Nov. 20, 2029 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 7442830 | Nov. 20, 2029 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 4MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | 7442830 | Nov. 20, 2029 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 2.3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | Nov. 20, 2022 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 3MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | Nov. 20, 2022 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
EQ 4MG BASE | NINLARO | TAKEDA PHARMS USA | N208462 | Nov. 20, 2015 | RX | CAPSULE | ORAL | Nov. 20, 2022 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Proteasome subunit beta type-5 | Enzyme | INHIBITOR | IC50 | 8.47 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Proteasome subunit beta type-1 | Enzyme | INHIBITOR | IC50 | 7.51 | SCIENTIFIC LITERATURE | ||||
Proteasome subunit beta type-2 | Enzyme | INHIBITOR | IC50 | 5.46 | SCIENTIFIC LITERATURE | ||||
ATP-dependent Clp protease proteolytic subunit | Enzyme | EC50 | 5.44 | CHEMBL |
ID | Source |
---|---|
71050168A2 | UNII |
D10130 | KEGG_DRUG |
1239908-20-3 | SECONDARY_CAS_RN |
4035138 | VANDF |
C3273711 | UMLSCUI |
CHEBI:90942 | CHEBI |
6V8 | PDB_CHEM_ID |
CHEMBL2141296 | ChEMBL_ID |
25183872 | PUBCHEM_CID |
DB09570 | DRUGBANK_ID |
CHEMBL3545432 | ChEMBL_ID |
CHEMBL1813256 | ChEMBL_ID |
9411 | INN_ID |
C548400 | MESH_SUPPLEMENTAL_RECORD_UI |
C000595706 | MESH_SUPPLEMENTAL_RECORD_UI |
8450 | IUPHAR_LIGAND_ID |
1723734 | RXNORM |
237159 | MMSL |
31293 | MMSL |
d08398 | MMSL |
715256005 | SNOMEDCT_US |
781324002 | SNOMEDCT_US |
784168005 | SNOMEDCT_US |
016599 | NDDF |
016600 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
NINLARO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-078 | CAPSULE | 2.30 mg | ORAL | NDA | 29 sections |
NINLARO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-079 | CAPSULE | 3 mg | ORAL | NDA | 29 sections |
NINLARO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-080 | CAPSULE | 4 mg | ORAL | NDA | 29 sections |
NINLARO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-230 | CAPSULE | 2.30 mg | ORAL | NDA | 33 sections |
NINLARO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-230 | CAPSULE | 2.30 mg | ORAL | NDA | 33 sections |
NINLARO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-390 | CAPSULE | 3 mg | ORAL | NDA | 33 sections |
NINLARO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-390 | CAPSULE | 3 mg | ORAL | NDA | 33 sections |
NINLARO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-400 | CAPSULE | 4 mg | ORAL | NDA | 33 sections |
NINLARO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63020-400 | CAPSULE | 4 mg | ORAL | NDA | 33 sections |